ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

Nicole Concin^{1

2}, Xavier Matias-Guiu^{3

4}, Ignace Vergote⁵, David Cibula⁶, Mansoor Raza Mirza⁷, Simone Marnitz⁸, Jonathan Ledermann⁹, Tjalling Bosse¹⁰, Cyrus Chargari¹¹, Anna Fagotti¹², Christina Fotopoulou¹³, Antonio Gonzalez Martin¹⁴, Sigurd Lax^{15

16}, Domenica Lorusso¹², Christian Marth¹⁷, Philippe Morice¹⁸, Remi A Nout¹⁹, Dearbhaile O'Donnell²⁰, Denis Querleu^{12

21}, Maria Rosaria Raspollini²², Jalid Sehouli²³, Alina Sturdza²⁴, Alexandra Taylor²⁵, Anneke Westermann²⁶, Pauline Wimberger²⁷, Nicoletta Colombo²⁸, François Planchamp²⁹, Carien L Creutzberg³⁰

Affiliations

¹ Department of Gynecology and Obstetrics, Innsbruck Medical University, Innsbruck, Austria nicole.concin@i-med.ac.at.
² Evangelische Kliniken Essen-Mitte, Essen, Germany.
³ Department of Pathology, Hospital Universitari Arnau de Vilanova, University of Lleida, CIBERONC, Irblleida, Spain.
⁴ Department of Pathology, Hospital Universitari de Bellvitge, University of Barcelona, Idibell, Spain.
⁵ Department of Gynecology and Obstetrics, Gynecologic Oncology, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium.
⁶ Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University, General University Hospital in Prague, Prague, Czech Republic.
⁷ Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
⁸ Department of Radiation Oncology, Medical Faculty of the University of Cologne, Cologne, Germany.
⁹ UCL Cancer Institute, University College, London, UK.
¹⁰ Department of Pathology, Leids Universitair Medisch Centrum, Leiden, Netherlands.
¹¹ Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.
¹² Division of Gynecologic Oncology, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy.
¹³ Department of Gynaecologic Oncology, Imperial College London Faculty of Medicine, London, UK.
¹⁴ Department of Medical Oncology, Clinica Universidad de Navarra, Madrid, Spain.
¹⁵ Department of Pathology, Hospital Graz II, Graz, Austria.
¹⁶ School of Medicine, Johannes Kepler University Linz, Linz, Austria.
¹⁷ Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria.
¹⁸ Department of Surgery, Institut Gustave Roussy, Villejuif, France.
¹⁹ Department of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
²⁰ Department of Medical Oncology, St James Hospital, Dublin, Ireland.
²¹ Department of Obstetrics and Gynecologic Oncology, University Hospital, Strasbourg, France.
²² Histopathology and Molecular Diagnostics, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
²³ Department of Gynecology with Center for Oncological Surgery, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
²⁴ Department of Radiation Oncology, Comprehensive Cancer Center, Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Vienna, Austria.
²⁵ Department of Gynaecology, Royal Marsden Hospital, London, UK.
²⁶ Department of Medical Oncology, Amsterdam University Medical Centres, Amsterdam, Noord-Holland, Netherlands.
²⁷ Department of Gynecology and Obstetrics, TU Dresden Medizinische Fakultat Carl Gustav Carus, Dresden, Germany.
²⁸ Gynecologic Oncology Program, European Institute of Oncology, IRCCS, Milan and University of Milan-Bicocca, Milan, Italy.
²⁹ Clinical Research Unit, Institut Bergonie, Bordeaux, France.
³⁰ Department of Radiation Oncology, Leiden University Medical Center, Leiden, Netherlands.

PMID: 33397713
DOI: 10.1136/ijgc-2020-002230

Free article

Practice Guideline

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

Nicole Concin et al. Int J Gynecol Cancer. 2021 Jan.

Free article

. 2021 Jan;31(1):12-39.

doi: 10.1136/ijgc-2020-002230. Epub 2020 Dec 18.

Authors

Affiliations

¹ Department of Gynecology and Obstetrics, Innsbruck Medical University, Innsbruck, Austria nicole.concin@i-med.ac.at.
² Evangelische Kliniken Essen-Mitte, Essen, Germany.
³ Department of Pathology, Hospital Universitari Arnau de Vilanova, University of Lleida, CIBERONC, Irblleida, Spain.
⁴ Department of Pathology, Hospital Universitari de Bellvitge, University of Barcelona, Idibell, Spain.
⁵ Department of Gynecology and Obstetrics, Gynecologic Oncology, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium.
⁶ Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University, General University Hospital in Prague, Prague, Czech Republic.
⁷ Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
⁸ Department of Radiation Oncology, Medical Faculty of the University of Cologne, Cologne, Germany.
⁹ UCL Cancer Institute, University College, London, UK.
¹⁰ Department of Pathology, Leids Universitair Medisch Centrum, Leiden, Netherlands.
¹¹ Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.
¹² Division of Gynecologic Oncology, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy.
¹³ Department of Gynaecologic Oncology, Imperial College London Faculty of Medicine, London, UK.
¹⁴ Department of Medical Oncology, Clinica Universidad de Navarra, Madrid, Spain.
¹⁵ Department of Pathology, Hospital Graz II, Graz, Austria.
¹⁶ School of Medicine, Johannes Kepler University Linz, Linz, Austria.
¹⁷ Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria.
¹⁸ Department of Surgery, Institut Gustave Roussy, Villejuif, France.
¹⁹ Department of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
²⁰ Department of Medical Oncology, St James Hospital, Dublin, Ireland.
²¹ Department of Obstetrics and Gynecologic Oncology, University Hospital, Strasbourg, France.
²² Histopathology and Molecular Diagnostics, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
²³ Department of Gynecology with Center for Oncological Surgery, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
²⁴ Department of Radiation Oncology, Comprehensive Cancer Center, Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Vienna, Austria.
²⁵ Department of Gynaecology, Royal Marsden Hospital, London, UK.
²⁶ Department of Medical Oncology, Amsterdam University Medical Centres, Amsterdam, Noord-Holland, Netherlands.
²⁷ Department of Gynecology and Obstetrics, TU Dresden Medizinische Fakultat Carl Gustav Carus, Dresden, Germany.
²⁸ Gynecologic Oncology Program, European Institute of Oncology, IRCCS, Milan and University of Milan-Bicocca, Milan, Italy.
²⁹ Clinical Research Unit, Institut Bergonie, Bordeaux, France.
³⁰ Department of Radiation Oncology, Leiden University Medical Center, Leiden, Netherlands.

PMID: 33397713
DOI: 10.1136/ijgc-2020-002230

Abstract

A European consensus conference on endometrial carcinoma was held in 2014 to produce multi-disciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly decided to update these evidence-based guidelines and to cover new topics in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide.

Keywords: pathology; radiation; surgery; uterine cancer.

PubMed Disclaimer

Conflict of interest statement

Competing interests: NCon: advisory boards for Seattle Genetics, AstraZeneca and Mersana, education fees from Medscape Oncology, and grants for travelling from Roche, Genmab and Amgen. IV: advisory boards for Amgen, AstraZeneca, Clovis Oncology, Carrick Therapeutics, Debiopharm International, F Hoffmann-La Roche, Genmab, GSK, Immunogen, Millenium Pharmaceuticals, MSD Belgium, Octimet Oncology, Oncoinvent, Pharmamar-Doctaforum Servicios, Roche, Sotio, Tesaro, Deciphera Pharmaceuticals and Verastem Oncology (fees for consulting to his university), contracted research (KU Leuven) for Oncoinvent AS and Genmab, corporate sponsored research for Amgen and Roche, and grants for travelling from Amgen, MSD/Merck, Roche, AstraZeneca and Tesaro. DC: advisory boards for AstraZeneca, Roche, Sotio and Novocure. MRM: personal financial interests for AstraZeneca, Biocard, Clovis Oncology, Geneos, Genmab, Karyopharm Therapeutics, Merck, Mersana, MSD, Oncology Venture, Pfizer, Roche, SeatleGenetics, SeraPrognostics, Sotio, Tesaro-GSK, ZaiLab; leadership role for Karyopharm Therapeutics, Sera Prognostics; institutional financial interests (study grants) for AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Pfizer, Tesaro-GSK, Ultimovacs. JL: advisory boards for AstraZeneca, Pfizer, GSK, Eisai, MSD/Merck, Artios Pharma, Regeneron, Amgen and Clovis Oncology, and grants for travelling from Clovis Oncology. CC: advisory boards for MSD, Takeda and GSK, conducting research for TherAguiX and Roche, and grants for travelling from Takeda. AF: advisory boards for GSK and Johnson & Johnson SpA, and grants for travelling from Pharmmar and MSD Italia. CF: advisory boards for AstraZeneca, Clovis, Ethicon, Roche, MSD, GSK and Tesaro, and grants for travelling from Sequana. AGM: speakers’ bureau activities for AstraZeneca, Pharmamar, Roche and GSK, advisory boards for Amgen, AstraZeneca, Clovis Oncology, Genmab, GSK, Immunogen, Merck Sharp & Dohme, Novartis, Oncoinvent, Pfizer/Merck, Pharmamar, Roche and Sotio, and grants for travelling from AstraZeneca, Pharmamar Roche and Tesaro. DL: advisory boards for Roche, Amgen, MSD, GSK, Clovis, AstraZeneca, Immunogen, Genmab, Pharmamar and Merck, and grants for travelling from Pharmamar, GSK, Roche and AstraZeneca. CM: consulting/advisory boards for Roche, Novartis, Amgen, MSD, AstraZeneca, Pfizer, Pharmamar, Cerulean, Vertex and Tesaro, funded research from EU, FWF, AstraZeneca and Roche, and honoraria/expenses from Roche, Novartis, Amgen, MSD, Pharmamar, AstraZeneca and Tesaro. JS: advisory boards for Roche, Eisei, MSD, AstraZeneca, Clovis, GSK and Tesaro. AT: advisory boards for Genmab; PW: advisory boards for Amgen, AstraZeneca, MSD, Novartis, Pfizer, Pharmamar, Lilly, Roche Pharma GmbH, TEVA, Eisai, Clovis and Tesaro, and grants for travelling from Roche Pharma GmbH, AstraZeneca, MSD, Amgen and Pfizer. NC: consulting and advisory services, speaking or writing engagements, public presentations for Roche, AstraZeneca, MSD, Pharmamar, Tesaro, GSK, Clovis, Advaxis, Pfizer, Takeda, Immunogen, Biocad, Amgen, Novartis and Ellipses, institutional financial interests for Roche, Pharmamar and AstraZeneca, and non-financial interests for ESMO clinical Guidelines (subject editor for gynecological cancer). XMG, SM, TB, SL, PM, RN, DOD, DQ, MRR, AS, AW, FP, and CLC: no conflicts of interest.

Comment in

Response to: Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with myometrial invasion) with chemoradiotherapy on the basis of p53abn?
Concin N, Matias-Guiu X, Creutzberg CL; ESGO-ESTRO-ESP Endometrial Carcinoma Guideline Working Group. Concin N, et al. Int J Gynecol Cancer. 2021 Jun;31(6):947. doi: 10.1136/ijgc-2021-002668. Epub 2021 Apr 28. Int J Gynecol Cancer. 2021. PMID: 33911002 No abstract available.
Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with myometrial invasion) with chemoradiotherapy on the basis of p53abn?
Merlotti A, Russi E, De Sanctis V. Merlotti A, et al. Int J Gynecol Cancer. 2021 Jun;31(6):946. doi: 10.1136/ijgc-2021-002630. Epub 2021 Apr 28. Int J Gynecol Cancer. 2021. PMID: 33911003 No abstract available.
Incorporating molecular profiling into endometrial cancer management requires prospective studies.
Amant F, McCluggage WG, Werner HMJ, Kasius JC, Krakstad C, Pijnenborg J. Amant F, et al. Int J Gynecol Cancer. 2021 Jun;31(6):944-945. doi: 10.1136/ijgc-2021-002705. Epub 2021 May 7. Int J Gynecol Cancer. 2021. PMID: 33962995 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- ClinicalTrials.gov

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

Affiliations

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

Authors

Affiliations

Abstract

Conflict of interest statement

Comment in

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical